文献速递创伤与烧伤心脑血管急症

轻创伤性脑损伤患者中胶质与神经元血液生物标志物与临床决策规则评估CT检查需求的比较

Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain Injury.
PubMed 文献 · JAMA Netw Open · 2022-03-01
一句话结论在轻创伤性脑损伤患者中,CCHR、NOC及GFAP联合UCH-L1生物标志物敏感性均为100%,CCHR特异性最高,CCHR联合GFAP诊断性能最优。

这项来自一级创伤中心的前瞻性队列研究纳入377例疑似轻创伤性脑损伤成人,比较GFAP与UCH-L1水平与3种验证过的临床决策规则(CCHR、NOC、NEXUS II)检测CT创伤性颅内病变的性能。结果显示CCHR、NOC及GFAP联合UCH-L1(切点67和189 pg/mL)敏感性均为100%,CCHR特异性最高(33%),NEXUS II敏感性83%、特异性52%;采用不同切点(30和327 pg/mL)会同时降低GFAP联合UCH-L1的敏感性和特异性。GFAP单标志物(不联合UCH-L1)对临床决策规则的改善最大,CCHR联合GFAP诊断性能最高(AUROC 0.88)。

要点

  • CCHR敏感性100%(95%CI 82%-100%)、特异性33%(95%CI 28%-39%)、NPV 100%(95%CI 96%-100%),在3种规则中特异性最高。
  • NOC敏感性100%(95%CI 82%-100%)、特异性16%(95%CI 12%-20%)、NPV 100%(95%CI 91%-100%)。
  • NEXUS II敏感性83%(95%CI 60%-94%)、特异性52%(95%CI 47%-58%)、NPV 98%(95%CI 94%-99%)。
  • GFAP与UCH-L1联合(切点67和189 pg/mL)敏感性100%(95%CI 82%-100%)、特异性25%(95%CI 20%-30%)、NPV 100%;切点改为30和327 pg/mL时敏感性91%(95%CI 70%-98%)、特异性20%(95%CI 16%-24%)、NPV 97%。
  • CCHR联合GFAP的AUROC为0.88,高于GFAP单用0.83、GFAP联合NEXUS II 0.83、GFAP联合NOC 0.85;GFAP单标志物对决策规则的改善最大。

适用人群与场景

  • 疑似轻创伤性脑损伤成人,伤后4小时内就诊于一级创伤中心。
  • 筛查2274例潜在患者,697例符合纳入标准,320例拒绝参与,最终377例入组;349例(93%)完成CT扫描并纳入分析。
  • 平均(SD)年龄40(16)岁;230例(66%)为男性;314例(90%)格拉斯哥昏迷评分15分;23例(7%)CT阳性。

诊断标准与关键阈值

  • 临床决策规则包括加拿大CT头规则(CCHR)、新奥尔良标准(NOC)和NEXUS II标准。
  • GFAP与UCH-L1联合切点分别为67和189 pg/mL时敏感性100%、特异性25%;切点为30和327 pg/mL时敏感性91%、特异性20%。

研究设计与关键结果

  • 研究设计:前瞻性队列研究,来自一级创伤中心;数据收集自2010年3月16日至2014年3月5日,2021年8月11日分析。
  • CCHR:敏感性100%(95%CI 82%-100%)、特异性33%(95%CI 28%-39%)、NPV 100%(95%CI 96%-100%)。
  • NOC:敏感性100%(95%CI 82%-100%)、特异性16%(95%CI 12%-20%)、NPV 100%(95%CI 91%-100%)。
  • NEXUS II:敏感性83%(95%CI 60%-94%)、特异性52%(95%CI 47%-58%)、NPV 98%(95%CI 94%-99%)。
  • GFAP与UCH-L1联合(切点67和189 pg/mL):敏感性100%(95%CI 82%-100%)、特异性25%(95%CI 20%-30%)、NPV 100%;切点30和327 pg/mL:敏感性91%(95%CI 70%-98%)、特异性20%(95%CI 16%-24%)、NPV 97%。
  • AUROC:GFAP单用0.83;GFAP联合NEXUS II 0.83;GFAP联合NOC 0.85;GFAP联合CCHR 0.88。
  • AUROC:UCH-L1单用0.72;UCH-L1联合NEXUS II 0.77;UCH-L1联合NOC 0.77;UCH-L1联合CCHR 0.79。
  • GFAP单标志物(不联合UCH-L1)对临床决策规则的改善最大。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CCHR、NOC及GFAP联合UCH-L1生物标志物具有同等高的敏感性,CCHR特异性最高;采用不同切点值会降低GFAP联合UCH-L1的敏感性和特异性。
  • 作者认为,使用GFAP可显著改善临床决策规则的性能,且不依赖于UCH-L1;CCHR联合GFAP具有最高的诊断性能。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In 2018, the combination of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase (UCH-L1) levels became the first US Food and Drug Administration-approved blood test to detect intracranial lesions after mild to moderate traumatic brain injury (MTBI). How this blood test compares with validated clinical decision rules remains unknown.

OBJECTIVES: To compare the performance of GFAP and UCH-L1 levels vs 3 validated clinical decision rules for detecting traumatic intracranial lesions on computed tomography (CT) in patients with MTBI and to evaluate combining biomarkers with clinical decision rules.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study from a level I trauma center enrolled adults with suspected MTBI presenting within 4 hours of injury. The clinical decision rules included the Canadian CT Head Rule (CCHR), New Orleans Criteria (NOC), and National Emergency X-Radiography Utilization Study II (NEXUS II) criteria. Emergency physicians prospectively completed data forms for each clinical decision rule before the patients' CT scans. Blood samples for measuring GFAP and UCH-L1 levels were drawn, but laboratory personnel were blinded to clinical results. Of 2274 potential patients screened, 697 met eligibility criteria, 320 declined to participate, and 377 were enrolled. Data were collected from March 16, 2010, to March 5, 2014, and analyzed on August 11, 2021.

MAIN OUTCOMES AND MEASURES: The presence of acute traumatic intracranial lesions on head CT scan (positive CT finding).

RESULTS: Among enrolled patients, 349 (93%) had a CT scan performed and were included in the analysis. The mean (SD) age was 40 (16) years; 230 patients (66%) were men, 314 (90%) had a Glasgow Coma Scale score of 15, and 23 (7%) had positive CT findings. For the CCHR, sensitivity was 100% (95% CI, 82%-100%), specificity was 33% (95% CI, 28%-39%), and negative predictive value (NPV) was 100% (95% CI, 96%-100%). For the NOC, sensitivity was 100% (95% CI, 82%-100%), specificity was 16% (95% CI, 12%-20%), and NPV was 100% (95% CI, 91%-100%). For NEXUS II, sensitivity was 83% (95% CI, 60%-94%), specificity was 52% (95% CI, 47%-58%), and NPV was 98% (95% CI, 94%-99%). For GFAP and UCH-L1 levels combined with cutoffs at 67 and 189 pg/mL, respectively, sensitivity was 100% (95% CI, 82%-100%), specificity was 25% (95% CI, 20%-30%), and NPV was 100%; with cutoffs at 30 and 327 pg/mL, respectively, sensitivity was 91% (95% CI, 70%-98%), specificity was 20% (95% CI, 16%-24%), and NPV was 97%. The area under the receiver operating characteristic curve (AUROC) for GFAP alone was 0.83; for GFAP plus NEXUS II, 0.83; for GFAP plus NOC, 0.85; and for GFAP plus CCHR, 0.88. The AUROC for UCH-L1 alone was 0.72; for UCH-L1 plus NEXUS II, 0.77; for UCH-L1 plus NOC, 0.77; and for UCH-L1 plus CCHR, 0.79. The GFAP biomarker alone (without UCH-L1) contributed the most improvement to the clinical decision rules.

CONCLUSIONS AND RELEVANCE: In this cohort study, the CCHR, the NOC, and GFAP plus UCH-L1 biomarkers had equally high sensitivities, and the CCHR had the highest specificity. However, using different cutoff values reduced both sensitivity and specificity of GFAP plus UCH-L1. Use of GFAP significantly improved the performance of the clinical decision rules, independently of UCH-L1. Together, the CCHR and GFAP had the highest diagnostic performance.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Papa L, Ladde JG, O'Brien JF, et al. Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain Injury. JAMA Netw Open. 2022. PMID: 35285924. doi:10.1001/jamanetworkopen.2022.1302

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。